This $815,215 Project Grant award from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) supports a comprehensive study on sex-based differences in Alzheimer's disease (AD) pathology and progression. The research aims to leverage neuroimaging techniques, plasma biomarkers, and tau PET imaging to investigate how sex and sex-based factors, such as reproductive period and APOE genotype, impact functional brain networks and the spread of tau pathology...
This $1,558,726 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a 5-year longitudinal investigation into the neurobiological changes that occur during the perimenopause and their impact on cognitive function and brain health. The University of Pittsburgh, the primary awardee, will recruit 224 women in the late reproductive to early menopausal transition stage and conduct comprehensive assessments of brain structure and function, cognition,...
This $1,758,779 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research by the Winifred Masterson Burke Medical Research Institute to assess neuronal vulnerability in the entorhinal cortex due to Alzheimer's disease pathology. The key objectives are to determine whether hyperexcitability in Alzheimer's disease is caused by dysfunction of excitatory or inhibitory neurons in the entorhinal cortex, and to modulate neuronal activities to...
This federal Project Grant award of $528,876.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Emory University will support a 5-year research study to investigate the genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and related dementias (AD/ADRD). The key objectives are to: Estimate genome-wide cis- and trans-acting quantitative trait loci (QTLs) for transcriptome-wide genes and proteome-wide proteins across multiple brain...
This Project Grant award, with a total funding amount of $4,619,796.00, was provided by the National Institute on Aging under the Aging Research program (CFDA 93.866). The grant was awarded to the Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences), a non-profit research organization located in Augusta, Georgia. The purpose of this grant is to investigate the use of noninvasive pulsed laser therapy as a potential therapeutic approach for brain protection in...
This federal Project Grant award, provided by the National Institute on Aging (CFDA 93.866 Aging Research), aims to investigate the mechanisms by which sex differences and angiotensin II signaling influence the development and progression of Alzheimer's disease (AD). The $2,114,698 grant, awarded to the University of North Texas Health Science Center at Fort Worth, will fund research over a 5-year period from Aug 2024 to Apr 2029. The key products and services to be delivered under this grant...
The National Institutes of Health National Institute on Aging awarded $3,024,000 under the Aging Research federal grant program (CFDA 93.866) to the Massachusetts General Hospital on September 30, 2022 for a project concluding on August 31, 2025. The award will support research into discovering sex-linked genes on the inactive X chromosome that may influence female vulnerability to Alzheimer's disease pathology. The awardee will employ genomic, transcriptomic, and epigenetic analysis to...
This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 - Aging Research aims to investigate the mechanisms by which the Alzheimer's disease risk factor APOE4 interacts with sex and aging to drive neuronal dysfunction and cognitive decline. The $804,450 award to the J. David Gladstone Institutes will fund a multi-level research effort leveraging advanced techniques like single-nucleus RNA sequencing and in vivo brain activity monitoring. The key objectives are to:...
This federal Project Grant award, valued at $550,627.00 and provided by the National Institute on Aging under the Aging Research program (CFDA 93.866), supports research into the role of oral microbially induced exosomes in the pathogenesis of Alzheimer's disease and related dementias (ADRD). The award, with a performance period from January 1, 2025 to November 30, 2029, is provided to the Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences), a non-profit...
The National Institute on Aging (CFDA 93.866 Aging Research) awarded a $148,568 Project Grant to Brandeis University to conduct research on the neurobiological mechanisms underlying daily life activity participation in older adults and its linkages to Alzheimer's disease pathology. The proposed research will use a multilevel, multimodal framework to study the behavioral and neurobiological mechanisms of age-related shifts in motivation to perform cognitively effortful activities, and directly...
This federal Project Grant award of $2,309,934 from the National Institute on Aging (NIA) Aging Research program (CFDA 93.866) supports research into the role of brain aromatase and its impact on Alzheimer's disease (AD) development and progression. The key objectives are to:
Examine whether downregulation or inhibition of aromatase is associated with worsened cognitive decline in AD rodent models, and if photobiomodulation (PBM) or estradiol (E2) treatment can prevent aromatase decline and cognitive deficits.
Test if brain aromatase mediates the beneficial effects of PBM therapy on local E2 production and cognitive improvements in different AD models.
Determine if PBM enhances synaptogenesis and spine formation via an aromatase/E2-irisin-BDNF signaling pathway in both in vivo and in vitro AD models.
The research will be conducted by the Augusta University Research Institute, Inc. (dba Georgia Health Sciences), a non-profit research organization, over the award period from September 2024 to August 2029. This project aims to elucidate the role of brain aromatase in AD pathogenesis and evaluate PBM as a potential therapeutic approach for preventing and managing AD, particularly addressing sex differences in the disease.